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Available online 5 December 2016Somatic mutations have a central role in cancer but their role in other diseases such as autoimmune disorders is
poorly understood. Earlier work has provided indirect evidence of rare somatic mutations in autoreactive
T-lymphocytes in multiple sclerosis (MS) patients but such mutations have not been identiﬁed thus far. We
analysed somaticmutations in blood in 16patientswith relapsingMS and 4with other neurological autoimmune
disease. To facilitate the detection of somatic mutations CD4+, CD8+, CD19+ and CD4−/CD8−/CD19− cell
subpopulations were separated. We performed next-generation DNA sequencing targeting 986 immune-
related genes. Somatic mutations were called by comparing the sequence data of each cell subpopulation to
other subpopulations of the same patient and validated by amplicon sequencing. We found non-synonymous
somatic mutations in 12 (60%) patients (10 MS, 1 myasthenia gravis, 1 narcolepsy). There were 27 mutations,
all different and mostly novel (67%). They were discovered at subpopulation-wise allelic fractions of 0.2%–4.6%
(median 0.95%). Multiple mutations were found in 8 patients. The mutations were enriched in CD8+ cells
(85% of mutations). In follow-up after a median time of 2.3 years, 96% of the mutations were still detectable.
These results unravel a novel class of persistent somatic mutations, many of which were in genes that
may play a role in autoimmunity (ATM, BTK, CD46, CD180, CLIP2, HMMR, IKFZF3, ITGB3, KIR3DL2, MAPK10,
CD56/NCAM1, RBM6, RORA, RPA1 and STAT3). Whether some of this class of mutations plays a role in disease is
currently unclear, but these results deﬁne an interesting hitherto unknown research target for future studies.ilja.janss
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STAT31. Introduction
Somatic mutations are non-inherited alterations in DNA that occur
in a progenitor cell and become transmitted to its descendant popula-
tion (clone). They arise at a low frequency by chance, typically during
DNA replication, and can be caused by environmental factors such as
chemicals or ionizing radiation. Virtually all cancer cells have such
acquired mutations and several types of somatic mutations in blood
leukocytes have been characterized in e.g. leukemias [1].
Besides patients with hematological cancers, relatively little is known
on the frequency and nature of somatic mutations in blood leukocytes.
Age-related somatic mutations that confer growth advantage have been
recently detected in blood in association with clonal hematopoiesison@hus.ﬁ (L. Jansson),
(P. Ellonen),
wad),
enari).
n open access article under[2–5]. Two large-scale studies have shed light to the landscape of blood
cell somatic mutations occurring in population cohorts not selected for
cancer or hematologic phenotypes [3,4]. Both studies tested whole
blood DNA and focused on mutations occurring with a large allelic frac-
tion of ca. 10–20% in whole exome sequence data [3] or in a set of 160
genes implicated in hematologic cancers [4]. Somatic mutations were
found in approximately 1%of subjects under age 50, and in10%of subjects
older than 70 years. Both studies identiﬁedmutational hotspots,DNMT3A,
TET2, and ASXLmutations constituted N2/3 of the mutations (2, 3).
There are only few studies on leukocyte somatic mutations in
autoimmune disease (other than somatic hypermutation of immuno-
globulin genes). Holzelova et al. [6] reported somatic mutations in FAS
in a fraction of CD4+ and CD8+ T-lymphocytes in children with an
autoimmune lymphoproliferative syndrome. Similar rare autoimmune
diseases have been described in conjunction with somatic mutations
in the NRAS and KRAS genes [7]. Whether somatic mutations have a
role in more common autoimmune disorders has not been established.
A recent study by us identiﬁed somatic mutations in the STAT3 gene in
CD8+ T-cells in 40% of patients with large granular lymphocyticthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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with rheumatoid arthritis signiﬁcantly more often than mutation
negative patients, suggesting a possible role of STAT3 mutations in
these autoimmune symptoms.
Multiple sclerosis (MS) is a chronic inﬂammatory disease of the cen-
tral nervous system and among themost common causes of neurological
disability in young adults. The cause ofMS is not known, but it is assumed
to be an autoimmune disorder. Multiple lines of evidence suggest that at
least relapsing forms ofMSwould be driven by blood leukocyte dysfunc-
tion. N100 genetic loci are known to be linked with MS predisposition,
the overwhelmingmajority ofwhich are in genes or regions active in leu-
kocytes [9,10]. The most potent drugs for relapsing MS (natalizumab,
alemtuzumab, ﬁngolimod, daclizumab) aremainly targeted against lym-
phocytes circulating in the blood [11]. Moreover, Epstein-Barr virus
(EBV) is a well-documented environmental risk factor of both MS as
well as lymphoid and epithelial malignancies, the risk of MS being espe-
cially high in association with EBV infectious mononucleosis [12].
Against this background, it is of interest to analyze blood leukocyte
somatic mutations in MS. Indirect evidence of somatic mutations has
been previously reported in MS by using the hypoxanthine guanine
phosphoribosyltransferase (HPRT) assay [13–15]. This assay measures
6-thioguanine resistance of cultured cells, caused by inactivating
somatic mutations of theHPRT gene or other mechanisms. The estimat-
ed mutation frequency in T-lymphocytes is approximately 5 × 10−6 in
adults [14]. Allegretta et al. reported on the presence of HPRT-
deﬁcient T-lymphocyte clones in MS and, interestingly, some of these
mutant clones, but not wild-type clones, were potentially autoreactive,
i.e. proliferated in response to a myelin autoantigen [13]. Another study
reported higher HPRT mutant frequency in MS patients' T lymphocytes
as compared to controls [15]. A pilot study on direct detection of somatic
mutations in MS has been reported [16]. The study was focused on sin-
gle CD4+ T-lymphocytes, derived from two MS patients' cerebrospinal
ﬂuid. In an exome sequencing analysis of 21 individual whole genome
ampliﬁed cells thousands of variants were reported, but the authors
concluded that they were unable to conﬁdently identify true somatic
mutations, as these could not be discerned from whole genome
ampliﬁcation induced mutational noise. The study points to technical
obstacles when mutations in small cell populations are screened.
In the present study we analysed whether nonsynonymous somatic
mutations can be reliably found in the blood. We enriched peripheral
blood mononuclear cells (PBMCs) into subpopulations and utilized
next-generation sequencing of 986 immune-related genes (with
additional validation sequencing), allowing the detection of mutations
with low allelic fractions (down to 0.1–0.2%). We addressed the follow-
ing questions. Are somatic mutations detectable with this approach?
What is their frequency among the patients and allelic fraction within
cell populations? Do the mutations preferentially occur in a particular
cell population? Are there mutational hotspots? This information
would provide important insights into the design of studies in larger
materials and reveal details about the general landscape of blood
somatic mutations in non-cancerous settings.
2. Results
2.1. Screening for somatic mutations in peripheral blood mononuclear cell
populations
We obtained blood samples from 20 patients. 16 of the patients had
relapsingMS, 2 had narcolepsy, one hadmyasthenia gravis, and one had
stiff person syndrome and systemic lupus erythematosus (clinical
details given in Table 1). We used immunomagnetic beads to enrich
PBMCs into CD4+, CD8+ and CD19+ cell populations and a remaining
CD4−CD8−CD19− triple negative cell population. These markers
were chosen to capture basic subgroups of interest.
We used high-depth next generation sequencing (NGS) to screen
the DNAs for somatic mutations. The sequencing covered all exonsof a panel of 986 immune-related genes (Table S1). We restricted
our sequencing efforts to this predeﬁned panel (referred to as
Immunopanel-986 from hereon) in order to cost-effectively approach a
target sequencing depth of up to 1000×. In total we successfully se-
quenced 71 cell populations obtained from the PBMCs of the 20 patients
(mean depths within coding regions: CD4+ 753x, CD8+ 723x, CD19+
671x, CD4−CD8−CD19− 491x). From this Immunopanel-986
sequencing data, we performed somatic variant calling to ﬁnd variants
that were detectable in a particular cell population andwere not present
in other (control) cell populations of the same patient (more details in
Materials and Methods, Screening phase data analysis). We were able
to produce a list of 154 putative somatic mutations for further validation
using another sequencing method (amplicon sequencing).
2.2. Amplicon sequencing conﬁrms 27 nonsynonymous somatic mutations
Using DNA from the same cell populations in which the putative
somatic variantswere called,we prepared validation PCR amplicons cor-
responding to the 154 putative nonsynonymous somatic variant calls.
We again employed NGS and sequenced the patient DNA amplicons
along with amplicons prepared from control DNA to an excessive
mean depth of over 100,000×.Wewere able validate 27 of the 154 var-
iant calls as true somatic mutations. Both screening and validation step
sequencing depth and allelic fractions for each conﬁrmed mutation are
given in Table S2, along with p-values for the somatic mutation calls.
A subset of 8 mutations were tested in two PCR replicates from
whole blood DNA. All mutations were detectable in whole blood DNA
in both replicates. The mean allelic fraction of these 8 mutations was
0.35% in whole blood as compared to 2.25% (6.4 fold higher) in the
enriched subpopulation of cells (Supplementary Table S3).
A technical reason for the inclusion of so many false positives
(n = 127; 82%) was found to be counting some sequence mismatches
twice, when the two opposite direction reads of paired end sequencing
overlapped on short DNA fragments. This inﬂated the read count for
some rare observations. In a post hoc analysis, we observed that
counting the mismatches present on such overlapping paired end
reads only once per pair eliminated the false positives, although with
a cost in sensitivity (missing 16 of the 27 true somatic variants).
2.3. Somatic mutation frequencies
Out of the 20 patients, we were able to validate somatic mutations in
12 (60%). Eight of the 12patients hadmultiplemutations (2–4mutations
per patient, Table 2). Ten of the patients with somaticmutations hadMS,
while the other two had myasthenia gravis and narcolepsy.
The highest allelic fraction observed for a somatic mutation was
4.6%,whichwould correspond to a clone size of 9.2% assuming a hetero-
zygous mutation. The lowest allelic fraction of a somatic mutation was
0.19% while the median allelic fraction of all validated mutations was
0.95%. Fig. 1 shows the distribution of allelic fractions.
2.4. Unique and predominantly novel mutations in each patient
Table 3 shows the 27 validated somatic mutations. In total, we
observed 23 single nucleotide variants (SNV) that were predicted to
result in an amino acid changes, 2 in-frame 3-bp deletions, one splice-
site SNV, and one premature stop-codon producing SNV. Each patient
had a unique mutation proﬁle – there were no mutational hotspots.
Two patients had mutations in the CD56/NCAM1 gene, but the
mutations were at different sites.
Out of the 27 somatic mutations, 19 (67%) were novel, i.e. they
were not found in COSMIC [17], dbSNP [18] or ExAC [19] databases,
whereas 8 of the somatic mutations could be found in at least one of
these databases. Nineteen (70%) of the mutations were predicted
deleterious by the CADD [20] algorithm (Table 3).
Table 1
Baseline characteristics of the patients.
Patient Diagnosis Immunological medication Age Sex Disease duration (years) Separated cell populationsa
MS-1 Multiple sclerosis Natalizumab 35 M 2 CD4+, CD8+, CD19+
MS-2 Multiple sclerosis Noneb 55 F 9 CD4+, CD8+, CD19+, CD4−CD8−CD19−
MS-3 Multiple sclerosis Natalizumab 38 M 4 CD4+, CD8+, CD19+, CD4−CD8−CD19−
MS-4 Multiple sclerosis Natalizumab 32 F 3 CD4+, CD8+, CD19+, CD4−CD8−CD19−
MG-5 Myasthenia gravis None 67 F 0.5 CD4+, CD8+, CD19+, CD4−CD8−CD19−
SP-6 Stiff-person syndrome (GAD antibody
positive), SLE
Rituximab, mycophenolate mofetil,
gammaglobulin
36 F 13 CD4+, CD8+, CD4−CD8−CD19−
MS-7 Multiple sclerosis Glatiramer acetate 57 F 13 CD4+, CD8+, CD19+, CD4−CD8−CD19−
MS-8 Multiple sclerosis Azathioprine 59 F 35 CD4+, CD8+, CD19+, CD4−CD8−CD19−,
CD28 ab stimulated CD8+
NL-9 Narcolepsy (type 2 non-cataplectic) None 24 M 3 CD4+, CD8+, CD19+, CD4−CD8−CD19−
MS-10 Multiple sclerosis Interferon beta 25 F 2 CD4+, CD8+, CD19+, CD4−CD8−CD19−
MS-11 Multiple sclerosis + Type 1 diabetes None 40 F 6 CD4+, CD8+, CD19+, CD4−CD8−CD19−
MS-12 Multiple sclerosis Interferon beta 46 F 0.5 CD4+, CD8+, CD19+, CD4−CD8−CD19−
MS-14 Multiple sclerosis None 48 F 7 CD4+, CD8+, CD19+
NL-16 Narcolepsy-cataplexy (type-2) None 22 M 3 CD4+, CD8+, CD19+
MS-17 Multiple sclerosis Natalizumab 58 F 15 CD4+, CD8+, CD19+
MS-19 Multiple sclerosis Glatiramer acetate 35 F 16 CD4+, CD8+, CD19+
MS-21 Multiple sclerosis Interferon beta 54 F 10 CD4+, CD8+, CD19+
MS-22 Multiple sclerosis None 43 F 0.5 CD4, CD8+, CD19+
MS-23 Multiple sclerosis None 29 F 0.5 CD4+, CD8+, CD19+
MS-24 Multiple sclerosis Interferon beta 22 F 1.5 CD4+, CD8+, CD19+
a Cell populations with adequate amount of DNA for sequencing are shown.
b Previous treatment with interferon-beta, glatiramer acetate, natalizumab, mitoxanthrone, and azathioprine.
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77M. Valori et al. / Clinical Immunology 175 (2017) 75–81We observed no association between patient's age (p = 0.23,
two-tailed t-test) or disease duration (p=0.93) andmutation positivity
in this dataset. Normal expression of the genes, in which mutations
were detected was analysed by RNA sequencing in reference cell
populations sorted according to the same protocol as all study samples
(the expression status is given in Table 3 and RNA sequencing
expression values in Table S4).
2.5. Enrichment of somatic mutations in the CD8+ cell population
Intriguingly, the clear majority (n = 23, 85%) of the 27 somatic
mutations were observed in the CD8+ cell population. Although we
sequenced a similar amount of CD4+ and CD19+ cells (based on
sequencing depths), we were not able to validate more than a single
somatic mutation in each of these cell populations (Table 4).
For the CD8+ and CD4+ cell populations, we performed T cell
receptor Vβ ﬂuorescence-activated cell sorting (FACS) analysis to
characterize clone sizes in the patient samples. Ten patients (50%) had
an expanded “large” CD8+ clone (see deﬁnition in Table S5 footnote),
but the presence of a large clone did not signiﬁcantly predict the
detection of a somatic mutation (p = 0.65, Table S5). Hence, preselec-
tion of the samples by T cell receptor Vβ FACS does not seem to facilitate
the detection of this type of mutant clones with low allelic fractions.
A representative T cell receptor Vβ FACS analysis of one patient
(MS-8) is given in Supplementary Fig. S1. The Vβ quantiﬁcations of all
20 patients are given in Supplementary Fig. S2.
2.6. Persistence of detected somatic mutations
We collected a second blood sample from each of the patients
whose initial sample contained oneormore somaticmutations (median
sampling interval 2.3 years). We separated the cell populationsTable 2
Number of somatic mutations discovered per patient.
N mutations Patients
4 MS-8, MS-19, MS-21
3 MS-2
2 MS-1, MS-3, NL-9, MS-12
1 MG-5, MS-14, MS-22, MS-23
0 MS-4, SP-6, MS-7, MS-10, MS-11, NL-16, MS-17, MS-24from PBMCs and again performed high depth amplicon sequencing in
order to examine whether the somatic mutations persisted. All but
one (26 of 27) of the somatic mutations were detected in the second
sample. There was no general trend towards increase or decrease in
allelic fraction: 14 mutations increased and 12 decreased in allelic
fraction (including one, which was not anymore detectable), while
one remained at the same level. The increases and decreases were
mostly 50% or less in magnitude (in 19 of the 27 mutations). Table S6
shows the detailed changes in somatic mutation allelic fractions over
time. One mutated CD8+ clone (carrying a deletion in the IKZF3
gene) increased 7-fold in allelic fraction from 2.3% to 16.4%. This MS
patient had changed treatment from baseline natalizumab, which in-
duced lymphocytosis (blood lymphocyte count was 4.09 × 10−6/ml)
to ﬁngolimod, which induced lymphopenia (blood lymphocyte count
was 0.66 × 10−6/ml). This data suggest that ﬁngolimod targets other
CD8+ populations more efﬁciently than the mutant clone. P-values
and related observation counts for persistence data are listed in
Table S7.Allelic fraction
0
0% 1% 2% 3% 4% 5%
Fig. 1. Distribution of the allelic fractions of validated somatic mutations.
Table 3
Successfully validated somatic mutations in decreasing order of allelic fraction.
Allelic
fraction
(validation)
Allelic
fraction
(discovery)
Sample Gene AA
change
CADD
score
4.63% 4.71% MS-12-CD8+ CD1C R89C 10.0
4.03% 2.71% MS-8-CD19+ TRAF2 409–410 LF/Lb 21.6c
2.88% 2.29% MS-19-CD8+ CD46 A250Tb 23.4c
2.81% 2.70% MS-21-CD8+ RBM6 P24Sb 25.3c
2.71% 2.70% MS-2-CD8+ A2ML1a R1001W 32.0c
2.28% 1.62% MS-1-CD8+ IKZF3 155–156 FT/Sb 22.9c
2.23% 2.14% MS-2-CD8+ BTK Splicingb 24.2c
1.58% 1.69% MS-19-CD8+ PTPMT1 I165Vb 17.0
1.58% 1.29% MG-5-others CD56/NCAM1 G417Rb 34.0c
1.36% 0.70% MS-19-CD8+ ITGA2a Q581K 16.4
1.22% 0.86% MS-21-CD8+ CD56/NCAM1 R358Xb 18.2
1.21% 1.68% MS-8-CD8+ RPA1 L394Pb 25.5c
0.98% 1.32% MS-8-CD8+ KIR3DL2 D392Y 23.4c
0.95% 1.15% MS-21-CD8+ RORA R533Q 23.0c
0.83% 1.23% MS-19-CD8+ PSG1a S23Tb 12.4
0.83% 1.04% MS-3-CD8+ HMMR E405Kb 26.5c
0.80% 1.31% NL-9-CD8+ C6a A298Pb 23.1c
0.68% 0.80% NL-9-CD8+ CLIP2 R932H 34.0c
0.59% 1.07% MS-1-CD8+ MBL2a A37S 8.9
0.46% 0.74% MS-2-CD4+ CD180 D526Yb 24.4c
0.45% 0.70% MS-21-CD8+ STAT3 D661Y 34.0c
0.40% 0.74% MS-22-CD8+ INSRa A119Vb 31.0c
0.35% 0.46% MS-14-CD8+ ITGB3 F229Lb 29.7c
0.32% 0.53% MS-8-CD8+ TLR7a N275Kb 0.009
0.23% 0.60% MS-3-CD8+ MAPK10a S316Fb 22.2c
0.19% 1.34% MS-12-others ATM L2519Vb 26.3c
0.19% 0.56% MS-23-CD8+ CFH V407Lb 0.001
The allelic fraction of a somatic mutation is calculated as the percentage of sequencing
reads that contain the variant base. Genomic coordinates are shown in Table S2. Sample
code consists of the patient number and a cell population speciﬁerwhere “others” denotes
the CD4−CD8−CD19− population.
a Gene not expressed in the target cell population type based on RNA sequencing data.
b Indicates a novel mutation.
c CADD scores of 20 or more can be considered predictably deleterious.
78 M. Valori et al. / Clinical Immunology 175 (2017) 75–812.7. Autoimmunity associated STAT3*D661Y mutation in CD8+ cells of an
MS patient
A notable observation was the presence of the STAT3*D661Y
mutation in the CD8+ subpopulation of an MS patient, at an allelic
fraction of 0.45% upon discovery and 0.74% in follow-up 19 months
later (Table 3, Table S6). This mutation has been reported in large
granular lymphocytic leukemia patients' CD8+ T-lymphocytes and
among thesepatients this particularmutation associateswithneutrope-
nia and autoimmune rheumatoid arthritis [8,21]. The MS patient with
this mutation did not have neutropenia or any other clear abnormalities
in blood (data not shown), nor did she have rheumatoid arthritis.
She responded poorly to treatments. She developed a relapse during
the initial beta-interferon treatment. Next she was treated with
natalizumab, but developed progressive disease course during treat-
ment and a relapse after cessation of natalizumab. Then, she started
dimethyl fumarate treatment, but developed side effects (nausea,
diarrhea, tachycardia) and during subsequent ﬁngolimod treatment she
developed gradual disease progression. Currently she is on teriﬂunomide
(started 2months ago) and has not had any relapses, disease progression
or signiﬁcant side-effects.Table 4
Number of validated somatic mutations per cell population.
Cell population type Mutations detected
CD4+ 1
CD8+ 23
CD19+ 1
CD4−CD8−CD19− 23. Discussion
We tested, whether somaticmutations can be detected in peripheral
blood mononuclear cells in patients with neurological autoimmune
disease, most of whom had MS. In contrast to previous population
studies [3,4] where mutations of allelic fraction above 10% were discov-
ered in whole blood, we applied a discovery pipeline for lower allelic
fractions. By enriching blood mononuclear cells into CD4+, CD8+,
CD19+ and other subsets and applying high depth next-generation
sequencing of 986 immune-related genes we were able to detect and
validate persistent somatic mutations in over half of the patients
enrolled. Mutations were found both in MS and other neurological
autoimmune disease patients in the present study. The initially
discovered mutations were present at allelic fractions between
0.19%–4.5% in each cell population. In whole blood the estimated allelic
fractions would be b0.5% for most of the mutations. We conﬁrmed this
estimate by directly sequencing 8 selectedmutations fromwhole blood,
where the observedmean allelic fractionwas 0.34% (range 0.06–0.56%).
These results demonstrate that high depth next generation sequencing
is a viable way to discover somatic mutations from non-cancer patients'
blood samples, evenwhen themutant clones are small. Importantly, the
results deﬁne an interesting hitherto unknown research target for
future studies. The major limitation of our study is that at this stage
we cannot make any conclusions on the pathogenic role of the
mutations. First, we did not analyze healthy controls and it is presently
not known, if persistent somatic mutations in CD8+ cells are also com-
mon in healthy adults. Secondly, we do not know, if some of themutant
clones are also present in the central nervous system. Third, it is unclear,
if some of these clones are able to react against own tissue either via
autoantigen recognition or bystander demyelination [22]. Hence,
further steps are needed to demonstrate pathogenicity of the mutant
clones. Recent analyses of MS patient's T-cell receptor Vβ repertoire
suggest that the same CD8+ clones present in MS plaques can also be
detected in the cerebrospinal ﬂuid and blood [23]. Further studies
seem therefore realistic and are required to test the possible role of
the mutated clones in disease, including sequencing of controls,
patients' cerebrospinal ﬂuid cells as well as analysis of antigen
speciﬁcities and other phenotypic features of the mutant clones.
The mean sequencing depth at sites where validated somatic muta-
tions were detected in the screening phase was 1062× (median 934×)
after duplicate read removal (Table S8). Therefore the target sequencing
depth should be set to at least 1000× in subsequent studies, with added
depth beyond this expected to generate more ﬁndings. With more
target genes/regions and more sequencing depth it is likely that more
mutations would have been discovered in the present dataset. It should
be noted that because of sequencing noise the depth cannot be
increased indeﬁnitely. The highest quality base calls that the Illumina
platform produces have a quality score estimate of around 1/10,000
errors, which was found to be empirically quite accurate in our data.
In order to ﬁnd somatic mutations as rare as 1/10,000 and beyond,
specialized techniques such as tagging DNA fragments with random
barcodes [24] would have to be employed.
A striking ﬁnding in our studywas the clear enrichment (85%) of the
somatic mutations in the CD8+ cell population. This enrichment may
stem from technical reasons (detectability) or reﬂect overall higher
mutational load in CD8+ cells. CD8+ memory cells have been shown
to produce larger clones than other populations [25] rendering muta-
tions more readily detectable. On the other hand, mutagenesis itself
may be especially prominent in CD8+ cells. CD8+ cells exhibit more
clonal expansions upon antigen stimulus than CD4+ cells [26] and
especially large clonal expansions of CD8 cells have been demonstrated
in infectious mononucleosis [27]. More mitoses generate more
mutations. Whether other biological reasons are also involved in
the enrichment of mutation in CD8 cells (e.g. higher sensitivity to
external mutagens, lower ﬁdelity of DNA repair, lower rate of mutant
clone elimination) is currently less clear. From an autoimmunity
79M. Valori et al. / Clinical Immunology 175 (2017) 75–81standpoint, activating mutations in CD8+ T cells are interesting
because of these cells' role as autoimmune effectors in a mouse
model [28], their high abundance in active MS lesions [29], and
signiﬁcant genetic effects of CD8+ cell's antigen recognition
molecules, HLA class I in MS [30].
We did not detect any mutational hotspots in this data as each
mutation was unique and all but two resided in distinct genes. A larger
analysis withmore target genes will be required to properly answer the
question of hotspot existence. All mutations that we discovered were
located in immune-related genes because we a priori selected only
these genes in our panel. Because of this, to answer whether mutations
accumulate in certain biological pathways would need a different type
of study design. A few potentially interestingmutations were observed.
The most prominent of these was the STAT3*D661Y mutation which is
known to be present in large granular lymphocytic leukemia cases
and associates with neutropenia and rheumatoid arthritis symptoms
[8,21]. Moreover, STAT3 is one of the susceptibility loci in MS [31].
A shortlist of other interesting mutations, based on gene expression in
the carrier cell population type (Table S4), mutation persistence
(Table S6) and predicted deleteriousness, includes ATM, BTK, CD46,
CD180, CLIP2, HMMR, IKFZF3, ITGB3, KIR3DL2, MAPK10, CD56/NCAM1,
RBM6, RORA, and RPA1 (Table 3). Previous studies utilizing the HPRT
assay (12–14) used somatic mutation as an index of T-cell ampliﬁcation
to capture autoreactive clones for subsequent T-cell receptor and
autoantigen characterization. Our present results demonstrate
mutations that are potentially more than just indexes or genomic
scars from past mitoses, their potential role in autoimmunity
warrants further research.4. Materials and methods
4.1. Study participants and sample collection
Patients for this studywere recruited at the Department of Neurology
of Helsinki University Hospital. This study has been approved by
the regional ethics committee at the Helsinki University Hospital
(Dno 83/13/03/01/2013). Each patient gave informed consent for
participating in the research.4.2. Cell separation and DNA extraction
Mononuclear cells were extracted from 120 to 140 ml venous EDTA
blood using Ficoll-Paque PLUS (GE Healthcare Bio-Sciences, Piscataway,
NJ, USA). First, 13 ml of Ficoll-Paque was added to a centrifuge tube.
Then, 9 ml of blood diluted with 28 ml of PBS was layered on top of it.
The tube was centrifuged at 800 ×g for 30 min after which the
mononuclear cell layer was transferred to a new tube with a pipette.
The cells were washed twice, using PBS and centrifugation at 500 ×g for
15 min and at 500 ×g for 10 min. From the mononuclear cells, positive
separation with MACS CD4, CD8 and CD19 antibody MicroBeads
(Miltenyi Biotec, Bergisch Gladbach, Germany) was performed using an
OctoMACS magnetic separator (Miltenyi Biotec) following the
manufacturers protocol. In addition to the CD4+, CD8+ and CD19+
fractions, a CD4−CD8−CD19− fraction was separated by using all of
the above bead types to give a negative selection. Catalogue numbers
for the used beads were 130-050-301 (CD19), 130-045-201 (CD8) and
130-045-101 (CD4). One separated CD8+ fraction was stimulated with
a CD28 antibody. From the separated cell populations, DNA and RNA
were extracted using the InviTrap Spin Universal RNA Mini Kit (Stratec
Biomedical, Birkenfeld, Germany) according to manufacturer's instruc-
tions. The purities of the separated CD4+, CD8+ and C19+ cells were
tested in a subsample by ﬂow cytometric analysis, in which the observed
purities were N90% for the CD4+ and CD8+ cells and N70% for the
CD19+ cells.4.3. Custom gene panel
A custom designed gene panel referred to as Immunopanel-986was
utilized for themutation screening step. The panel consists of 986 genes
related to immunity and cancer, the bulk of which originated from the
curated InnateDB database [32] with additional targets such as genes
related to the JAK-STAT pathway compiled from different publications
(for full gene list, see Table S1).
4.4. Screening phase library preparation and sequencing
DNA from the separated cell populations was fragmented using a
Covaris S2 instrument (Covaris, Woburn, MA, USA) and then a sequenc-
ing library was prepared according to the NEBNext DNA Sample Prep
Master Mix Set 1 (New England BioLabs, Ipswich, MA, USA) manual
with some minor exceptions. Target enrichment for all exons of the
genes included in the Immunopanel-986 gene panel was achieved with
theNimblegen SeqCap exon capture system(RocheNimbleGen,Madison,
WI, USA). Library Puriﬁcationwas performedusingAgencourt AMPureXP
beads (Beckman Coulter, Brea, CA, USA). The target enriched library was
sequenced with a HiSeq 2500 instrument (Illumina, San Diego, CA, USA)
using paired end 101 bp reads.
4.5. Screening phase data analysis
Sequencing reads were mapped against the GRCh37 reference
genome using BWA-MEM [33] after adapter trimming with the
Trimmomatic [34] software. PCR duplicates were removed using Picard
MarkDuplicates (http://broadinstitute.github.io/picard). VarScan2 [35]
was used for somatic mutation calling. Each sequenced cell population
acted in turn as the VarScan2 “tumor” (target) sample from which
somatic mutations were called, andmerged data from the other cell pop-
ulations originating from the same patient acted as the VarScan2 “nor-
mal” (control) sample. The variant detection strategy of VarScan2 was
augmented with custom logic to enable deﬁning a cutoff for somatic var-
iants of high enough conﬁdence to be included in a validation step. The
custom steps were as follows: ﬁrst, all mismatches against the reference
genome were tested using a binomial test with error rate estimated
from the data to discard random non-systematic sequencing noise,
Bonferroni corrected by the number of tests (size of target area ∗ 4, a
test for each possible base). The variant sites were ﬁltered for strand
bias and against possible contamination from germline variants from
other samples. Then the target (“tumor”) and control (“normal”) samples
were compared using Fisher's exact test to show somatic status for sites
that passed the ﬁrst ﬁlters. The putative somatic variant list from all sam-
ples was then FDR corrected using the Benjamini and Hochberg method
with FDR cutoff set to 0.05 to yield a ﬁnal list of variants to feed into val-
idation. Variants were annotated using the ANNOVAR [36] package. Exe-
cution of the analysis pipeline was performed using the Snakemake [37]
software.
4.6. Validation and re-analysis of mutations by amplicon sequencing
PCR amplicons for each of the putative somatic variants identiﬁed
in the screening phase were prepared following the “Illumina 16S
Metagenomic Sequencing Library Preparation” [38] protocol, adjusted
for targets other than the bacterial 16S gene. Brieﬂy, all designed PCR
primer pairs had their forward primer prepended with the sequence
TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG while the reverse primer
was prepended with the sequence GTCTCGTGGGCTCGGAGATGTGTATA
AGAGACAG. Primer oligos were ordered from Sigma Aldrich (St. Louis,
MO, USA) and PCR was carried out using the KAPA HiFi polymerase
(KapaBiosystems,Wilmington,MA,USA). A second roundof PCRutilizing
the overhang sequences was then performed to incorporate full Illumina
sequencing adapters using primers from the Nextera XT Index Kit
(Illumina, San Diego, CA, USA). The amplicons were puriﬁed after both
80 M. Valori et al. / Clinical Immunology 175 (2017) 75–81PCR steps using Agencourt AMPure XP beads (Beckman Coulter, Brea, CA,
USA). The resulting library was sequenced using a MiSeq instrument
(Illumina, San Diego, CA, USA) using 200 bp paired end reads. Amplicon
sequencing was performed using DNA from the same cell populations
in which a putative somatic variant was identiﬁed. In addition, amplicons
of all targets were prepared using separate donor control DNA. Eight mu-
tations that were validated in the ﬁrst sequencing run were also tested in
whole blood DNA using the same protocol. Sequencing reads were
mapped against the GRCh37 reference genome using BWA-MEM [33]
after adapter trimming with the Trimmomatic [34] software. VarScan2
[35] was used in validation mode to report somatic p-values (Fisher's
exact test) at each of the genomic coordinates containing a variant to be
validated. Data from patient cell populations served as the VarScan
“tumor” input and data from the control DNA amplicons as the VarScan
“normal” input. The data was also inspected directly from samtools [39]
mpileup output. The somatic variants from Immunopanel HiSeq data
were considered successfully veriﬁed if they met a p-value threshold of
0.001 in this data, Bonferroni corrected by the number of veriﬁcations
performed and did not display strand bias. Variant deleteriousness
predictionswere performed using the CADD [20] algorithm,with a scaled
score of at least 20 considered predictably deleterious.
4.7. FACS
An analysis of T cell receptor Vβ (beta chain variable region)
repertoire was performed in CD4+ and CD8+ cells. The IO Test Beta
Mark TCR Vβ Repertoire Kit (Beckman Coulter, Brea, CA, US) was used
and ﬂow cytometry was performed with a BD FACSAria II instrument
(BD Biosciences, San Jose, CA, USA). A cell population was considered to
contain a large clonal expansion if a Vβ type was seen in 10% or more of
the cells and was present at over twice of the intensity of a population
control frequency.
4.8. RNA sequencing
Gene expression in the target cell subpopulations (CD4+, CD8+,
CD19+ and CD4−/CD8−/CD19−) was analysed by RNA sequencing
of twoMS patients: MS17 and one patient (MS-0), whowas not included
to the somatic mutation analysis (female, no treatment, age 42).
Additionally, CD8+ target cell basal RNA expression was analysed in
two patients (MS-7, MS-8) and in one patient (MS-8) after stimulation
with CD3 and CD28 antibodies [40]. Sequencing libraries were prepared
using a strand-speciﬁc kit (New England BioLabs, Ipswich, MA, USA)
and sequenced with the MiSeq instrument (Illumina, San Diego, CA,
USA) with at least 25 million 300 bp read pairs produced per library.
Reads were aligned using TopHat2 [41] and expression quantiﬁed using
HTSeq-Count [42] and a custom script. The expression data is given in
Table S4. Genes were considered expressed, when the cut-off 1 was
reached in the FPKM value.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.clim.2016.11.018.
Acknowledgements
This study has been supported by the Helsinki University Hospital
(grants TYH2013407 and TYH 2014248 for PJT; TYH 2014234 for SM),
Biogen Finland (grant 3756 for PJT), Mutliple Sclerosis Foundation of Fin-
land (2013 for PJT, 2016 for MV), European Research Council (project M-
IMM for SM) Academy of Finland (grant 134150 for PJT, 136181 for SM),
the Finnish Cancer Institute (SM), and University of Helsinki. The authors
wish to acknowledge CSC – IT Center for Science, Finland, for computa-
tional resources and Dr. Nina Peitsaro and Noora Aarnio in the
Biomedicum Helsinki Flow cytometry core facility for FACS services. We
thank Mr. Harri Salo, Dr. Jarno Honkanen and Prof. Outi Vaarala for
CD28 stimulation assay. We thank Prof. Kimmo Porkka for discussions
in the study design.References
[1] I.R. Watson, K. Takahashi, P.A. Futreal, L. Chin, Emerging patterns of somatic
mutations in cancer, Nat. Rev. Genet. 14 (2013) 703–718.
[2] L. Busque, J.P. Patel, M.E. Figueroa, A. Vasanthakumar, S. Provost, Z. Hamilou, L.
Mollica, J. Li, A. Viale, A. Heguy, Recurrent somatic TET2 mutations in normal elderly
individuals with clonal hematopoiesis, Nat. Genet. 44 (2012) 1179–1181.
[3] G. Genovese, A.K. Kähler, R.E. Handsaker, J. Lindberg, S.A. Rose, S.F. Bakhoum, K.
Chambert, E. Mick, B.M. Neale, M. Fromer, Clonal hematopoiesis and blood-cancer
risk inferred from blood DNA sequence, N. Engl. J. Med. 371 (2014) 2477–2487.
[4] S. Jaiswal, P. Fontanillas, J. Flannick, A. Manning, P.V. Grauman, B.G. Mar, R.C.
Lindsley, C.H. Mermel, N. Burtt, A. Chavez, Age-related clonal hematopoiesis
associated with adverse outcomes, N. Engl. J. Med. 371 (2014) 2488–2498.
[5] M. Xie, C. Lu, J. Wang, M.D. McLellan, K.J. Johnson, M.C. Wendl, J.F. McMichael, H.K.
Schmidt, V. Yellapantula, C.A. Miller, Age-related mutations associated with clonal
hematopoietic expansion and malignancies, Nat. Med. 20 (2014) 1472–1478.
[6] E. Holzelova, C. Vonarbourg, M. Stolzenberg, P.D. Arkwright, F. Selz, A. Prieur, S.
Blanche, J. Bartunkova, E. Vilmer, A. Fischer, Autoimmune lymphoproliferative
syndrome with somatic Fas mutations, N. Engl. J. Med. 351 (2004) 1409–1418.
[7] J.E. Niemela, L. Lu, T.A. Fleisher, J. Davis, I. Caminha,M. Natter, L.A. Beer, K.C. Dowdell,
S. Pittaluga, M. Raffeld, V.K. Rao, J.B. Oliveira, Somatic KRAS mutations associated
with a human nonmalignant syndrome of autoimmunity and abnormal leukocyte
homeostasis, Blood 117 (2011) 2883–2886.
[8] H.L. Koskela, S. Eldfors, P. Ellonen, A.J. van Adrichem, H. Kuusanmäki, E.I. Andersson,
S. Lagström, M.J. Clemente, T. Olson, S.E. Jalkanen, Somatic STAT3 mutations in large
granular lymphocytic leukemia, N. Engl. J. Med. 366 (2012) 1905–1913.
[9] International Multiple Sclerosis Genetics Consortium, Wellcome Trust Case
Control Consortium 2. Genetic risk and a primary role for cell-mediated immune
mechanisms in Multiple Sclerosis, Nature 476 (2011) 214–219.
[10] International Multiple Sclerosis Genetics Consortium, Analysis of immune-related
loci identiﬁes 48 new susceptibility variants for multiple sclerosis, Nat. Genet. 45
(2013) 1353–1360.
[11] D.M. Wingerchuk, B.G. Weinshenker, Disease modifying therapies for relapsing
multiple sclerosis, BMJ 354 (2016) i3518.
[12] A. Ascherio, K.L. Munger, EBV and autoimmunity, Curr. Top. Microbiol. Immunol.
390 (2015) 365–385.
[13] M. Allegretta, J.A. Nicklas, S. Sriram, R.J. Albertini, T cells responsive to myelin basic
protein in patients with multiple sclerosis, Science 247 (1990) 718.
[14] R.J. Albertini, K.L. Castle, W.R. Borcherding, T-cell cloning to detect the mutant
6-thioguanine-resistant lymphocytes present in human peripheral blood, Proc.
Natl. Acad. Sci. U. S. A. 79 (1982) 6617–6621.
[15] S. Sriram, Longitudinal study of frequency of HPRT mutant T cells in patients with
multiple sclerosis, Neurology 44 (1994) 311–315.
[16] A.K. Kemppinen, A. Baker, W. Liao, B. Fiddes, J. Jones, A. Compston, M. Ban, S. Sawcer,
Exome sequencing in single cells from the cerebrospinal ﬂuid in multiple sclerosis,
Mult. Scler. 20 (2014) 1564–1568.
[17] S.A. Forbes, D. Beare, P. Gunasekaran, K. Leung, N. Bindal, H. Boutselakis, M. Ding, S.
Bamford, C. Cole, S. Ward, C.Y. Kok, M. Jia, T. De, J.W. Teague, M.R. Stratton, U.
McDermott, P.J. Campbell, COSMIC: exploring the world's knowledge of somatic
mutations in human cancer, Nucleic Acids Res. 43 (2015) D805–D811.
[18] S.T. Sherry, M.H. Ward, M. Kholodov, J. Baker, L. Phan, E.M. Smigielski, K. Sirotkin,
dbSNP: the NCBI database of genetic variation, Nucleic Acids Res. 29 (2001)
308–311.
[19] M. Lek, K. Karczewski, E. Minikel, K. Samocha, E. Banks, T. Fennell, A. O'Donnell-
Luria, J. Ware, A. Hill, B. Cummings, Analysis of protein-coding genetic variation in
60,706 humans, bioRxiv 2015, p. 030338.
[20] M. Kircher, D.M. Witten, P. Jain, B.J. O'Roak, G.M. Cooper, J. Shendure, A general
framework for estimating the relative pathogenicity of human genetic variants,
Nat. Genet. 46 (2014) 310–315.
[21] H.L. Rajala, T. Olson, M.J. Clemente, S. Lagstrom, P. Ellonen, T. Lundan, D.E. Hamm,
S.A. Zaman, J.M. Lopez Marti, E.I. Andersson, A. Jerez, K. Porkka, J.P. Maciejewski,
T.P. Loughran, S. Mustjoki, The analysis of clonal diversity and therapy responses
using STAT3 mutations as a molecular marker in large granular lymphocytic
leukemia, Haematologica 100 (2015) 91–99.
[22] J.S. Haring, L.L. Pewe, S. Perlman, Bystander CD8 T cell-mediated demyelination after
viral infection of the central nervous system, J. Immunol. 169 (2002) 1550–1555.
[23] M. Salou, A. Garcia, L. Michel, A. Gainche-Salmon, D. Loussouarn, B. Nicol, F. Guillot,
P. Hulin, S. Nedellec, D. Baron, Expanded CD8 T-cell sharing between periphery and
CNS in multiple sclerosis, Ann. Clin. Transl. Neurol. 2 (2015) 609–622.
[24] M.W. Schmitt, S.R. Kennedy, J.J. Salk, E.J. Fox, J.B. Hiatt, L.A. Loeb, Detection of
ultra-rare mutations by next-generation sequencing, Proc. Natl. Acad. Sci. U. S. A.
109 (2012) 14508–14513.
[25] Q. Qi, Y. Liu, Y. Cheng, J. Glanville, D. Zhang, J.Y. Lee, R.A. Olshen, C.M. Weyand, S.D.
Boyd, J.J. Goronzy, Diversity and clonal selection in the human T-cell repertoire,
Proc. Natl. Acad. Sci. U. S. A. 111 (2014) 13139–13144.
[26] M.K. Maini, G. Casorati, P. Dellabona, A. Wack, P.C. Beverley, T-cell clonality in
immune responses, Immunol. Today 20 (1999) 262–266.
[27] M.F. Callan, N. Steven, P. Krausa, J.D. Wilson, P.A. Moss, G.M. Gillespie, J.I. Bell, A.B.
Rickinson, A.J. McMichael, Large clonal expansions of CD8 T cells in acute infectious
mononucleosis, Nat. Med. 2 (1996) 906–911.
[28] E.S. Huseby, D. Liggitt, T. Brabb, B. Schnabel, C. Ohlen, J. Goverman, A pathogenic role
for myelin-speciﬁc CD8(+) T cells in a model for multiple sclerosis, J. Exp. Med. 194
(2001) 669–676.
[29] H. Babbe, A. Roers, A. Waisman, H. Lassmann, N. Goebels, R. Hohlfeld, M. Friese, R.
Schroder, M. Deckert, S. Schmidt, R. Ravid, K. Rajewsky, Clonal expansions of
CD8(+) T cells dominate the T cell inﬁltrate in active multiple sclerosis lesions as
81M. Valori et al. / Clinical Immunology 175 (2017) 75–81shown bymicromanipulation and single cell polymerase chain reaction, J. Exp. Med.
192 (2000) 393–404.
[30] M.A. Friese, K.B. Jakobsen, L. Friis, R. Etzensperger, M.J. Craner, R.M. McMahon, L.T.
Jensen, V. Huygelen, E.Y. Jones, J.I. Bell, Opposing effects of HLA class I molecules
in tuning autoreactive CD8 T cells in multiple sclerosis, Nat. Med. 14 (2008)
1227–1235.
[31] E. Jakkula, V. Leppä, A. Sulonen, T. Varilo, S. Kallio, A. Kemppinen, S. Purcell, K.
Koivisto, P. Tienari, M. Sumelahti, Genome-wide association study in a high-risk
isolate for multiple sclerosis reveals associated variants in STAT3 gene, Am. J.
Hum. Genet. 86 (2010) 285–291.
[32] K. Breuer, A.K. Foroushani, M.R. Laird, C. Chen, A. Sribnaia, R. Lo, G.L. Winsor, R.E.
Hancock, F.S. Brinkman, D.J. Lynn, InnateDB: systems biology of innate immunity
and beyond—recent updates and continuing curation, Nucleic Acids Res. 41
(2013) D1228–D1233.
[33] H. Li, Aligning sequence reads, clone sequences and assembly contigs with BWA-
MEM, arXiv preprint arXiv:1303.3997, 2013.
[34] A.M. Bolger, M. Lohse, B. Usadel, Trimmomatic: a ﬂexible trimmer for Illumina
sequence data, Bioinformatics 30 (2014) 2114–2120.
[35] D.C. Koboldt, Q. Zhang, D.E. Larson, D. Shen, M.D. McLellan, L. Lin, C.A. Miller, E.R.
Mardis, L. Ding, R.K. Wilson, VarScan 2: somatic mutation and copy numberalteration discovery in cancer by exome sequencing, Genome Res. 22 (2012)
568–576.
[36] K. Wang, M. Li, H. Hakonarson, ANNOVAR: functional annotation of genetic variants
from high-throughput sequencing data, Nucleic Acids Res. 38 (2010), e164.
[37] J. Koster, S. Rahmann, Snakemake–a scalable bioinformatics workﬂow engine,
Bioinformatics 28 (2012) 2520–2522.
[38] Illumina. 16SMetagenomic Sequencing Library Preparation, http://support.illumina.
com/documents/documentation/chemistry_documentation/16s/16s-metagenomic-
library-prep-guide-15044223-b.pdf.
[39] H. Li, B. Handsaker, A. Wysoker, T. Fennell, J. Ruan, N. Homer, G. Marth, G. Abecasis,
R. Durbin, 1000 genome project data processing subgroup. The sequence alignment/
map format and SAMtools, Bioinformatics 25 (2009) 2078–2079.
[40] J. Honkanen, J.K. Nieminen, R. Gao, K. Luopajarvi, H.M. Salo, J. Ilonen, M. Knip, T.
Otonkoski, O. Vaarala, IL-17 immunity in human type 1 diabetes, J. Immunol. 185
(2010) 1959–1967.
[41] D. Kim, G. Pertea, C. Trapnell, H. Pimentel, R. Kelley, S.L. Salzberg, TopHat2: accurate
alignment of transcriptomes in the presence of insertions, deletions and gene
fusions, Genome Biol. 14 (2013) (R36-2013-14-4-r36).
[42] S. Anders, P.T. Pyl, W. Huber, HTSeq–a python framework to work with high-
throughput sequencing data, Bioinformatics 31 (2015) 166–169.
